Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases; Breast cancer; Carcinoma
- Focus Pharmacodynamics
- 22 Mar 2019 Status changed from active, no longer recruiting to completed.
- 25 Jan 2018 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.
- 29 Dec 2017 Status changed from recruiting to active, no longer recruiting.